drugset
drugset / Trial / NCT07633756

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

NCT07633756 ↗

Phase 1 Not yet recruiting 15 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Timeline

Start
2026-10-19
Primary completion
2029-12-26
Completion
2031-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject GTAEXS617 Unknown 10 mg Oral

Indications

leiomyosarcoma